GlassScriptPhysician profile
Irfan Ansari
NPI 1043207228
$6,845.99
in general payments reported to CMS, 2019-2025
28 companies · $266 in 2025
The $266 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $3,520 · 2021: $627 · 2022: $944 · 2023: $618 · 2024: $421 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.44 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $3,051.59 | 2020-2025 | Idosetr |
| Alcon Vision LLC | $866.70 | 2019-2025 | Argos, Rocklatan, Clareon |
| Johnson & Johnson Surgical Vision, INC. | $400.97 | 2019-2022 | |
| Abbvie INC. | $343.15 | 2022-2025 | Xen Glaucoma Treatment System |
| Regeneron Healthcare Solutions, INC. | $325.39 | 2020-2022 | |
| Genentech USA, INC. | $268.58 | 2022-2023 | Vabysmo |
| Sight Sciences, INC. | $252.66 | 2019-2022 | |
| Allergan, INC. | $233.93 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $143.99 | 2022 | |
| Sun Pharmaceutical Industries INC. | $143.99 | 2019 | |
| Aerie Pharmaceuticals, INC. | $133.14 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $128.63 | 2023-2024 | Omidria, Rayone Spheric, Rayone Aspheric |
| Eyevance Pharmaceuticals LLC | $77.09 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $70.06 | 2019-2022 | |
| Harrow Eye, LLC | $68.85 | 2023-2025 | Triesence, Iheezo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $64.68 | 2019-2021 | |
| Rxsight INC | $49.25 | 2022-2024 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb Americas INC. | $38.34 | 2024 | Ic-8 Apthera Iol |
| New World Medical,INC. | $31.45 | 2021-2022 | |
| Steris Corporation | $25.00 | 2025 | |
| Biotissue Holdings INC. | $23.51 | 2024 | |
| Astellas Pharma US INC | $18.22 | 2023 | |
| Ocular Therapeutix, INC. | $17.77 | 2024 | Dextenza |
| Horizon Therapeutics Plc | $17.51 | 2020 | |
| Carl Zeiss Meditec USA, INC. | $14.96 | 2025 | |
| Lkc Technologies, INC. | $13.64 | 2025 | |
| Ivantis, INC | $11.75 | 2021 | |
| Integra Lifesciences Corporation | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irfan Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.